[HTML][HTML] Macrophages promote polycystic kidney disease progression

KI Swenson-Fields, CJ Vivian, SM Salah, JD Peda… - Kidney international, 2013 - Elsevier
KI Swenson-Fields, CJ Vivian, SM Salah, JD Peda, BM Davis, N Van Rooijen, DP Wallace…
Kidney international, 2013Elsevier
Renal M2-like macrophages have critical roles in tissue repair, stimulating tubule cell
proliferation and, if they remain, fibrosis. M2-like macrophages have also been implicated in
promoting cyst expansion in mouse models of autosomal dominant polycystic kidney
disease (ADPKD). While renal macrophages have been documented in human ADPKD,
there are no studies in autosomal recessive polycystic kidney disease (ARPKD). Here we
evaluated the specific phenotype of renal macrophages and their disease-impacting effects …
Renal M2-like macrophages have critical roles in tissue repair, stimulating tubule cell proliferation and, if they remain, fibrosis. M2-like macrophages have also been implicated in promoting cyst expansion in mouse models of autosomal dominant polycystic kidney disease (ADPKD). While renal macrophages have been documented in human ADPKD, there are no studies in autosomal recessive polycystic kidney disease (ARPKD). Here we evaluated the specific phenotype of renal macrophages and their disease-impacting effects on cystic epithelial cells. We found an abundance of M2-like macrophages in the kidneys of patients with either ADPKD or ARPKD and in the cystic kidneys of cpk mice, a model of ARPKD. Renal epithelial cells from either human ADPKD cysts or noncystic human kidneys promote differentiation of naive macrophages to a distinct M2-like phenotype in culture. Reciprocally, these immune cells stimulate the proliferation of renal tubule cells and microcyst formation in vitro. Further, depletion of macrophages from cpk mice indicated that macrophages contribute to PKD progression regardless of the genetic etiology. Thus, M2-like macrophages are two-pronged progression factors in PKD, promoting cyst cell proliferation, cyst growth, and fibrosis. Agents that block the emergence of these cells or their effects in the cystic kidney may be effective therapies for slowing PKD progression.
Elsevier